Pharma & Biotech

The telehealth provider Hims & Hers officially launched operations in Canada on December 4, 2025. This strategic move was executed...

Despite a challenging year for its share price, BioNTech concludes 2025 in a stronger strategic and financial position than market...

A wave of institutional investment and a strategic push to expedite a key drug approval are reinforcing the bullish narrative...

The German biotech firm BioNTech is decisively pivoting beyond its pandemic-era identity, placing a substantial strategic bet on mRNA oncology....

Investors in Novo Nordisk have reason for renewed optimism following a challenging period. The Danish pharmaceutical giant received a significant,...

Friday's trading activity for Ocugen presented a market conundrum. While the share price itself declined, a surge in bullish options...

The independent journey of CureVac as a publicly traded company has reached its conclusion. The Tübingen-based vaccine developer is now...

The equity of InnoCan Pharma continues to experience significant downward momentum. Closing at EUR 4.52 in the previous session, the...

In a strategic maneuver aimed at enhancing its financial flexibility, biotechnology firm Inmune Bio has modified the terms for a...

Shares of Viking Therapeutics gained approximately 2.9% to $36.42 following a pivotal regulatory decision that is reshaping the market for...